Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XMT-1522 · 1 trial · 3 indications
Evaluate adverse events and use of concomitant medication use after XMT-1522 doses
| Arm | Type | Description |
|---|---|---|
| Dose Escalation and Confirmation | EXPERIMENTAL | XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose. |
| Name | Type | Description |
|---|---|---|
| XMT-1522 | DRUG | one intravenous dose administered in-clinic every 21 days |
Inclusion Criteria: * Able and willing to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease via RECIST * Resolution of all toxic side effects from prior oncology treatments * Adequate organ function as measured by various blood param...
Top 20 of 92 competitors
XMT-1522 is an investigational small molecule being developed for the treatment of advanced breast cancer. It is currently in Phase 1 clinical development and has been studied in patients with advanced breast cancer expressing HER2. The drug is not yet approved and remains under clinical investigation.
XMT-1522 is an antibody drug conjugate that targets HER2, a protein commonly expressed in certain breast cancers. By targeting HER2, the drug aims to deliver its therapeutic effect directly to cancer cells that express this marker, potentially improving treatment outcomes for patients with HER2-expressing advanced breast cancer.
XMT-1522 is being developed by Day One Biopharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol DAWN. The company is focused on advancing this investigational therapy for patients with advanced breast cancer.
XMT-1522 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials, though it remains under investigation for advanced breast cancer.
XMT-1522 has been studied in a Phase 1 clinical trial with the identifier NCT02952729. This trial, titled 'Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,' enrolled 120 participants and has been completed. The study was conducted in the United States and included patients with advanced breast cancer, as well as advanced nonsmall cell lung cancer and advanced gastric cancer.